New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Stock Information for Gamida Cell Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Gamida Cell Ltd.

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
Kodiak Sciences Announces Proposed Public Offering of Common Stock
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Kodiak Sciences to Present at Upcoming Investor Conferences
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (?90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)
Kodiak Sciences to Present at American Chemical Society Fall 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.